更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 M Update 1Q25 Behind; Innovative Transition Ongoing Reaction to earnings April 30, 2025 04:07 AM GMT Fosun Pharmaceutical | Asia Pacific Morgan Stanley Asia Limited+ Yanru Tao Equity Analyst Yanru.Tao@morganstanley.com +852 3963-1041 Alexis Yan, CFA Equity Analyst Alexis.Yan@morganstanley.com +852 2239-7953 Impact to our thesis Financial results versus consensus Direction of next 12-month Unchanged Meaningful shortfall Meaningful revision lower consensus EPS Key Takeaways 1Q25 R ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 30 April 2025 | 12:55PM HKT Hong Kong Exchanges (0388.HK): 1Q25 First Take: in-line; Buy HKEX reported 1Q25 EPS of HK$3.23, up 38% yoy, 2% higher vs GSe. Revenue was modestly ahead and costs slightly below GSe. EBITDA was 2% higher, and eff. tax rate was 16%, in-line with GSe. And hence, NPAT was 2% above GSe. That said, profit excluding investment income was 6% below GSe. However, excluding the HK$90mn FCA payment, the miss was 3% on profit excluding II. We would expect a muted ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 China Healthcare Equities Takeaways on tariffs from clients and expert calls China We held joint marketing with HSBC global healthcare analysts Rajesh Kumar and Damayanti Kerai, as well an expert call, discussing the US tariff impact on China's and the global pharmaceutical supply chain. Below are our key takeaways: Tariff impact from highest to lowest: medical consumables, devices, drugs. The exact timeline and scope of tariffs remains unclear, but we expect tariffs on US pharm ...

28 Apr 2025 01:08:15 ET │ 11 pages 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 China Technology & Communications EU, US, SH Marketing Feedback CITI'S TAKE We met with almost 60 institutional investors in past three weeks in Europe, the US and Shanghai. Given US reciprocal tariffs announced on 2 April, investors' key discussions were focused on tariff impact to Apple/Nvidia chain, China retaliation beneficiaries, China semis localization, foldable iPhone, Xiaomi and China AI development. European investors are more positiv ...

View in browser 在浏览器中查看 TMTB Morning Wrap TMTB 早间 简报 TMT BREAKOUT TMT 突破 MAY 5 ∙ PAID 已付费 READ IN APP 在应用中阅读 QQQs -1% to start the day as Trump calls for tariffs on foreign made movies. BTC -1.5%. China -50bps. Yields mixed with the 10 year up 2bps while the 2 year is down slightly. QQQs 下跌 1%，特朗普呼吁对外国制造的电影征收关税，市场开盘如此反 应。BTC 下跌 1.5%。中国下跌 50 个基点。收益率表现不一，10 年期上涨 2 个基点，而2 年期则略有下跌。 Another big week of earnings. NOW analyst day starts today - 4:30pm est. 又是一个重要的财报周。NOW 分析师日今天开始 - 东部时间下午 4:30。 We'll hit Tech News ...

Summary of ServiceNow (NOW) 2025 Investor Day Company Overview - **Company**: ServiceNow (NOW) - **Event**: 2025 Investor Day - **Date**: May 5, 2025 - **Location**: Las Vegas Core Industry Insights - **Industry**: Enterprise Software - **Focus**: ServiceNow aims to be the defining enterprise software company of the 21st century, referred to as "Desco 21C" [6][33] Key Points and Arguments 1. **Company Growth and Positioning**: - ServiceNow is entering a period of strength, with significant scaling and a strong brand presence [5][11] - The company has a no layoff pledge, which has helped maintain talent during macroeconomic disruptions [12] 2. **Financial Performance**: - ServiceNow has consistently focused on profitability and leverage, unlike many competitors who had to adapt post-pandemic [12] - The company has a strong free cash flow margin, which is appreciated by shareholders [13] 3. **Market Position and Competitive Advantage**: - ServiceNow is recognized as the "AI operating system of the enterprise" by industry leaders [24] - The company has expanded its Total Addressable Market (TAM) significantly with innovations like RaptorDB and workflow data fabric [15][16] 4. **AI Integration and Innovation**: - ServiceNow is leveraging agentic AI to transform enterprise operations, emphasizing the importance of speed and integration [19][21] - The company has introduced new capabilities such as AI Control Tower, AI Agent Fabric, and AI Agent Studio to enhance AI agent collaboration [52][53] 5. **Customer Success Stories**: - Notable clients include AstraZeneca and Siemens, showcasing significant operational efficiencies achieved through ServiceNow's platform [49][50] - Over 85% of Fortune 500 companies utilize ServiceNow, indicating strong market penetration [48] 6. **Future Growth and Projections**: - ServiceNow aims to reach $30 billion in revenue, with several products projected to surpass $1 billion in Annual Contract Value (ACV) by 2026 [47][48] - The company is positioned to double its product offerings exceeding $1 billion in ACV by 2028 [47] Additional Important Insights - **Cultural and Operational Strength**: - ServiceNow emphasizes a culture of trust and transparency, which has been pivotal in building relationships with the financial community [4][8] - The company has a strong focus on innovation, with over 6,000 innovations delivered in the past year alone [40] - **Technological Advancements**: - RaptorDB is highlighted as the world's fastest database, significantly enhancing performance metrics for clients [29][90] - The Workflow Data Fabric allows seamless integration of data across various systems, enhancing operational efficiency [93] - **Market Trends and Challenges**: - The rise of AI presents both opportunities and challenges, with many enterprises struggling with data readiness for AI applications [88] - ServiceNow's solutions aim to address fragmentation and improve AI readiness across organizations [39][89] - **Strategic Partnerships**: - Collaborations with major tech companies like Microsoft, Google, and AWS are crucial for expanding ServiceNow's capabilities and market reach [53][109] This summary encapsulates the key insights and strategic directions discussed during the ServiceNow 2025 Investor Day, highlighting the company's growth trajectory, market positioning, and innovative approaches to enterprise software solutions.

Summary of Aptose Biosciences Conference Call Company Overview - **Company**: Aptose Biosciences - **Focus**: Clinical stage precision oncology company developing Tuspitinib for acute myeloid leukemia (AML) treatment [2][12] Industry Context - **Disease**: Acute Myeloid Leukemia (AML) - **Characteristics**: Aggressive cancer of the bone marrow and blood, primarily affecting patients aged 65 and older [5][6] - **Current Treatment**: Standard of care is a two-drug cocktail (Venaza: Venetoclax and Azacitidine) [6][9] - **Survival Rates**: Five-year survival rate for patients aged 65+ is approximately 9% [6] Core Points and Arguments - **Need for Improved Therapy**: - Current therapies have high rates of refractoriness (one-third of patients do not respond) and limited overall survival (median of 14.7 months for responders) [7][8] - Need for therapies that are broadly active across all genetic subtypes of AML [9][12] - **Tuspitinib's Role**: - Described as a safe, mutation-agnostic third drug to be added to the Venaza backbone [12][48] - Demonstrated excellent safety profile, convenient administration (once daily oral tablets), and broad activity against various AML mutations [13][48] - Potential market opportunity exceeding $1 billion annually [14] - **Clinical Trials**: - **Tuscany Trial**: Focused on newly diagnosed AML patients, aiming to select optimal dosing for pivotal studies [19][38] - Initial dosing started at 40 mg, escalated to 80 mg, with promising results in terms of complete remissions and minimal toxicity [20][22][24] - Patients achieving complete remission (CR) and minimal residual disease (MRD) negativity, indicating potential for durable responses [26][37] - **Regulatory Status**: - Orphan drug designation and fast track status received from the FDA [18] - Required to start trials in relapsed/refractory patients before moving to newly diagnosed patients [16] Important but Overlooked Content - **Patient Case Studies**: - Multiple case studies presented showing diverse mutation profiles and successful outcomes with Tuspitinib [30][34][36] - Highlighted the drug's effectiveness in patients with challenging mutations like TP53, which are often excluded from clinical trials [29][34] - **Upcoming Milestones**: - Data presentation at the European Hematology Association meeting and the American Society of Hematology meeting planned for later in the year [40][42] - Selection of pivotal trial dose expected within the year [38][49] - **Company Structure**: - Small team of 15 full-time employees, with a strong advisory board including key opinion leaders in AML and MDS [43][45] Conclusion - Aptose Biosciences is positioned to address significant unmet needs in AML treatment with its lead drug Tuspitinib, supported by promising clinical data and a strategic focus on broad applicability across genetic subtypes. The company is on track for pivotal trials and has garnered interest from major pharmaceutical companies.

enGene Holdings (ENGN) 2025 Conference May 05, 2025 02:00 PM ET Speaker0 For our next presentation, it's from NGIN, and we have the pleasure of having Ron Cooper, the CEO, here to present for us. So take it away, Ron. Thank you. Speaker1 Well, good afternoon, everybody. It's a real pleasure to be here. You know, first of all, thanks to the conference organizers. It's great to be back in back in Canada. NGEN is a company form formed in Canada. Our headquarters is in Montreal. Our labs are there, and we have ...

Clean Harbors (CLH) Conference Summary Industry Overview - Clean Harbors is the largest hazardous industrial waste service company in North America, focusing primarily on hazardous waste with some medical waste services due to incineration capabilities [4][10] - The waste industry is becoming more integrated, covering solid, industrial, and medical waste [4] Macroeconomic Outlook - The macroeconomic outlook has improved since the beginning of the year, with a strong pipeline and growth observed in April [7][8] - Despite concerns about cyclicality, Clean Harbors has shown resilience, with no signs of customers reducing demand [8][20] Business Segments Environmental Services - The Environmental Services segment has improved margins by 500 basis points over the last six to eight years, attributed to new incinerator capacity, better pricing strategies, and operational efficiencies [10][11] - The company has experienced 12 consecutive quarters of year-over-year EBITDA margin growth in this segment [17] Used Oil and Safety Clean Solutions - The used oil segment has faced profitability challenges post-pandemic, but a shift in strategy to prioritize pricing over volume has led to improved stability [81][86] - The company processes approximately 250 million gallons of used motor oil annually, converting it into base oil [82] Capacity and Market Dynamics - There is ample landfill capacity, but incineration capacity is constrained due to the complex nature of waste streams [28][30] - Clean Harbors has added new incineration capacity and expects this to be absorbed by the market due to ongoing demand [30][34] Regulatory Environment and PFAS - Clean Harbors has introduced a total PFAS solution, which includes testing, remediation, and disposal services, with projected revenue growth of 10% to 20% in this area [64][70] - The company is actively involved in addressing PFAS issues, with a long-term view on regulatory developments and market needs [68][69] Mergers and Acquisitions - The company has expanded its market share through acquisitions, allowing for better pricing discipline and stability in the Environmental Services segment [50][52] - Future M&A strategies will focus on geographic expansion and enhancing capabilities in waste management [53] Conclusion - Clean Harbors is positioned well within the hazardous waste industry, demonstrating resilience against macroeconomic challenges and adapting its business strategies to maintain profitability and growth [17][19][88]

Summary of Donaldson Company (DCI) FY Conference Call - May 05, 2025 Company Overview - **Company**: Donaldson Company (DCI) - **Industry**: Filtration technology - **Market Cap**: Approximately $8.7 billion - **Employees**: About 14,000, with two-thirds in production - **History**: Over 100 years in operation, with a strong focus on filtration technology and innovation - **Dividend Growth**: Part of the S&P High Yield Dividend Aristocrat fund, with nearly 30 years of annual dividend increases [10][11] Core Business and Strategy - **Filtration Leadership**: Donaldson is a leader in filtration technology, focusing on leveraging its technology across various markets rather than chasing specific markets [4][5] - **Market Opportunities**: The company aims to meet evolving environmental and operational goals through advanced filtration solutions, particularly in on-road transportation and industrial applications [5][6] - **Recurring Revenue**: Approximately 66% of revenue is recurring, driven by a "razor-razor blade" model where initial equipment sales lead to ongoing filter sales [13][26] - **Growth Segments**: Key segments include mobile solutions, industrial solutions, aerospace and defense, and life sciences, with a focus on connected services and aftermarket business [11][12][20] Financial Performance - **Revenue**: Reported revenue for fiscal year 2024 was $3.6 billion, with a forecasted growth of 0% to 4% for fiscal year 2025 [15][17] - **Earnings Per Share (EPS)**: Adjusted EPS for fiscal year 2024 was $3.42, with a midpoint guidance of over $3.6 for fiscal year 2025 [15][17] - **CAGR**: Sales CAGR of 4% and earnings growth CAGR of 13% over recent years, indicating strong operational performance [16][17] Market Dynamics and Risks - **Alternative Power Solutions**: The company is exploring opportunities in alternative power solutions, including hydrogen fuel cells and hybrid equipment, which may present more opportunities than risks [21][36] - **Tariff Management**: Donaldson has a natural hedge against tariffs, with 75% of production consumed in the same region, minimizing supply chain disruptions [23][25] - **Customer Relationships**: Strong relationships with large manufacturers create high barriers to entry for competitors, emphasizing the importance of trust and technology in customer solutions [19][20] Life Sciences and Bioprocessing - **Expansion into Life Sciences**: Donaldson has made several acquisitions in the bioprocessing space, focusing on disruptive technologies rather than "me too" products [8][52] - **Acquisitions**: The company has acquired four companies in the bioprocessing sector, with a focus on bioreactors and innovative technologies [53][54] - **Long-Term Vision**: The life sciences segment is still in early stages, with a focus on strategic growth and partnerships to enhance market presence [56][60] Capital Allocation and Shareholder Returns - **Capital Deployment**: Priorities include organic investment (21%), share repurchase (34%), and M&A (20%), with a focus on business growth [28][29] - **Shareholder Returns**: The company emphasizes returning value to shareholders through dividends and share repurchases [17][29] Conclusion - **Outlook**: Donaldson is well-positioned to capitalize on growth opportunities in filtration technology and life sciences, with a strong focus on innovation, customer relationships, and strategic market expansion [30][37]